Your browser is no longer supported. Please, upgrade your browser.
Settings
VVUS VIVUS, Inc. daily Stock Chart
VVUS [NASD]
VIVUS, Inc.
Index- P/E3.43 EPS (ttm)0.32 Insider Own0.90% Shs Outstand105.67M Perf Week5.77%
Market Cap116.24M Forward P/E- EPS next Y-0.45 Insider Trans-76.73% Shs Float99.40M Perf Month5.77%
Income35.00M PEG4.28 EPS next Q-0.13 Inst Own34.80% Short Float6.04% Perf Quarter-5.98%
Sales135.90M P/S0.86 EPS this Y124.80% Inst Trans-5.51% Short Ratio8.25 Perf Half Y-14.73%
Book/sh0.17 P/B6.47 EPS next Y-15.40% ROA12.00% Target Price10.40 Perf Year-10.57%
Cash/sh2.46 P/C0.45 EPS next 5Y0.80% ROE-445.40% 52W Range0.93 - 1.47 Perf YTD-4.35%
Dividend- P/FCF- EPS past 5Y19.10% ROI21.40% 52W High-23.81% Beta0.91
Dividend %- Quick Ratio7.70 Sales past 5Y- Gross Margin90.40% 52W Low20.43% ATR0.04
Employees65 Current Ratio8.10 Sales Q/Q76.50% Oper. Margin49.70% RSI (14)67.32 Volatility4.40% 3.86%
OptionableYes Debt/Eq13.57 EPS Q/Q91.80% Profit Margin25.70% Rel Volume1.12 Prev Close1.10
ShortableYes LT Debt/Eq13.05 EarningsMay 03 AMC Payout0.00% Avg Volume727.71K Price1.12
Recom2.30 SMA208.06% SMA506.46% SMA200-0.42% Volume802,920 Change1.82%
May-04-16Downgrade WallachBeth Buy → Hold
Nov-05-15Upgrade WallachBeth Hold → Buy $2.30 → $2.80
Jul-31-15Reiterated RBC Capital Mkts Outperform $6 → $4
Jan-23-15Initiated RBC Capital Mkts Outperform $6
Feb-25-14Reiterated WallachBeth Hold $11 → $8
Nov-15-13Initiated WallachBeth Hold $11
Oct-03-13Upgrade Cowen Hold → Outperform $19
Jul-19-13Downgrade Needham Buy → Hold
Jan-18-13Reiterated MLV & Co Buy $40 → $21
Sep-24-12Reiterated Needham Buy $38 → $32
Jul-19-12Reiterated MLV & Co Buy $34 → $40
Jul-18-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
Jul-18-12Downgrade Brean Murray Buy → Hold
Apr-30-12Reiterated MLV & Co Buy $30 → $34
Feb-23-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
Feb-23-12Upgrade Brean Murray Sell → Hold $2
Feb-23-12Reiterated MLV & Co Buy $22 → $30
Feb-23-12Reiterated JMP Securities Mkt Outperform $16 → $45
Jan-17-12Reiterated MLV & Co Buy $16 → $22
Jan-05-12Initiated Rodman & Renshaw Mkt Perform
May-25-17 02:13PM  Aerie's Ophthalmic Candidate Positive in Registration Trial Zacks
10:42AM  Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer Zacks
10:27AM  Regeneron Presents Positive Phase II Data on HoFH Candidate Zacks
08:15AM  Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session Zacks
07:23AM  Horizon (HZNP) Sells European Rights for Procysbi & Quinsair Zacks
07:11AM  Novartis (NVS) Reports Positive Data on Ultibro Breezhaler Zacks
May-24-17 04:15PM  Thomas B. King Joins VIVUS' Board of Directors Marketwired
11:08AM  Achaogen's Plazomicin Gets Breakthrough Therapy Designation Zacks
10:38AM  5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio Zacks
10:27AM  Theravance/Mylan Presents Phase III Data on COPD Candidate Zacks
09:17AM  Ultragenyx Receives Priority Review for rhGUS from FDA Zacks
May-23-17 05:23PM  BioLineRx Makes Regulatory Submission for Trial of BL-8040 Zacks
05:21PM  Merck Presents Phase II Data on Chronic Cough Candidate Zacks
04:41PM  Roche's Arthritis Drug Gets FDA Nod for Label Expansion Zacks
04:06PM  Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint Zacks
10:49AM  Catalyst Pharmaceuticals Focuses on Development of Firdapse Zacks
10:38AM  Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study Zacks
10:33AM  AstraZeneca Sells Marketing Rights to Seloken in Europe Zacks
May-22-17 04:46PM  Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab Zacks
08:52AM  Amgen Evenity Approval Derailed on Cardiovascular Side Effect Zacks
08:50AM  Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose Zacks
May-19-17 05:21PM  Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug Zacks
09:48AM  Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA Zacks
May-18-17 06:13PM  Incyte (INCY) Announces Positive Data on Enzyme Inhibitor Zacks
10:23AM  J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021 Zacks
10:21AM  Concert Pharma Falls After Clinical Hold on Hair Loss Drug Zacks
09:53AM  Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion Zacks
May-17-17 06:14PM  Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status Zacks
05:55PM  Alexion's (ALXN) Strensiq Results Positive in Long-Term Study Zacks
11:51AM  Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss Zacks
10:07AM  Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth Zacks
09:59AM  Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss Zacks
09:48AM  Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now Zacks
May-16-17 06:14PM  Celgene's (CELG) Revlimid Looks Solid on Label Expansion Zacks
06:13PM  Aerie's (AERI) Rhopressa NDA Sufficient for FDA Review Zacks
06:02PM  Minerva (NERV) Provides Phase III Development Strategy for MIN-101 Zacks
03:31PM  Why Is Vertex Pharma (VRTX) Stock Soaring This Year? Zacks
10:21AM  BioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains Zacks
May-15-17 10:56AM  Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4 Zacks
10:30AM  AbbVie and J&J Present Positive Imbruvica Leukemia Data Zacks
May-10-17 09:52AM  Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales Zacks
May-09-17 09:46AM  Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss Zacks
May-07-17 07:46PM  Edited Transcript of VVUS earnings conference call or presentation 3-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-04-17 10:37AM  VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y Zacks
May-03-17 06:04PM  Vivus reports 1Q loss Associated Press
04:10PM  VIVUS Reports 2017 First Quarter Financial Results Marketwired
08:25AM  Investor Network: VIVUS, Inc. to Host Earnings Call Accesswire
Apr-25-17 08:00AM  VIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference Marketwired
Apr-10-17 03:50AM  VIVUS (VVUS) Down 14.1% Since Earnings Report: Can It Rebound? Zacks
Mar-30-17 09:30AM  Orexigen Releases Q4 Results, Vivus Reacquires Stendra from Sanofi Accesswire
Mar-28-17 11:11AM  VIVUS to Regain Commercial Rights for Stendra from Sanofi Zacks
11:07AM  Orexigen Inks Commercialization Deal for Contrave, Stock Up
Mar-27-17 08:54AM  Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi MarketWatch
08:54AM  Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi at MarketWatch
08:36AM  VIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta
08:30AM  VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi Marketwired
Mar-15-17 11:16AM  7 Most Popular Diet Pills That Work Fast Without Exercise Insider Monkey
11:16AM  7 Most Popular Diet Pills That Work Fast Without Exercise at Insider Monkey
10:29AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017 Capital Cube
10:29AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017
Mar-14-17 01:04PM  VIVUS INC Financials
12:04PM  Top 10 Long/Short Estimize Signal Scores [Week 3/13]
Mar-13-17 04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Mar-10-17 09:30AM  Markets Rally Late to Close in the Green: Today's Research Reports on Immunomedics and VIVUS Accesswire -6.61%
Mar-09-17 10:59AM  VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y Zacks +16.35%
Mar-08-17 11:37PM  Edited Transcript of VVUS earnings conference call or presentation 8-Mar-17 9:30pm GMT Thomson Reuters StreetEvents
05:38PM  Vivus posts 4Q profit
04:17PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:10PM  VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results Marketwired
04:05PM  VIVUS INC Files SEC form 10-K, Annual Report
07:07AM  Q4 2016 VIVUS Inc Earnings Release - After Market Close
Feb-28-17 08:00AM  VIVUS Announces Date of 2016 Fourth Quarter Business Update and Financial Results Teleconference Marketwired
Feb-23-17 09:39AM  [2/23] This Weeks Earnings Revisions Movers +5.41%
Feb-22-17 09:45AM  Biotech's Rally Shows No Signs of Slowing Down: Today's Reports on Eyegate Pharmaceuticals and VIVUS Accesswire
Jan-31-17 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-18-17 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-17-17 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-11-17 03:24PM  VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan-10-17 08:33AM  VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-09-17 04:07PM  VIVUS INC Files SEC form 8-K, Other Events
09:00AM  VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH) Marketwired
Jan-03-17 04:20PM  VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?
Dec-29-16 05:29PM  4 Biotech Stocks with Bright Prospects in 2017
Dec-27-16 02:05PM  ETFs with exposure to VIVUS, Inc. : December 27, 2016 -5.56%
Dec-14-16 12:37AM  Do Hedge Funds Love VIVUS, Inc. (VVUS)? at Insider Monkey
Dec-13-16 01:42PM  ETFs with exposure to VIVUS, Inc. : December 13, 2016
Dec-05-16 11:10AM  Increased Earnings Estimates Seen for VIVUS (VVUS): Can It Move Higher?
Dec-01-16 04:20PM  5 Top Performing Biotechnology Stocks of November +5.22%
Nov-21-16 08:25AM  VIVUS (VVUS) Shows Strength: Stock Adds 5.1% in Session
Nov-18-16 01:43PM  ETFs with exposure to VIVUS, Inc. : November 18, 2016 +5.13%
Nov-14-16 04:12PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Submission of Matters to a Vote of Secur
11:25AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
Nov-11-16 02:51PM  VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3
Nov-09-16 09:25PM  Edited Transcript of VVUS earnings conference call or presentation 9-Nov-16 9:30pm GMT
06:25PM  Vivus reports 3Q loss
04:44PM  VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Security
04:10PM  VIVUS Reports 2016 Third Quarter Financial Results Marketwired
07:07AM  Q3 2016 VIVUS Inc Earnings Release - After Market Close
Oct-26-16 05:00PM  VIVUS Announces Date of 2016 Third Quarter Business Update and Financial Results Teleconference Marketwired
Oct-12-16 09:20AM  Mylan Up on EpiPen Medicaid Settlement, Cuts 2016 Outlook
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Varghese Santosh TChief Medical OfficerApr 04Sale1.0844047573,597Apr 06 06:33 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 10Sale1.1777,00090,24410,466,700Mar 10 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 09Sale1.21722,400873,24910,543,700Mar 10 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 08Sale1.05350,000368,34011,266,100Mar 10 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 07Sale1.08145,100156,15111,616,100Mar 07 05:18 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 06Sale1.1014,80016,23011,761,200Mar 07 05:18 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 03Sale1.1132,90036,36311,776,000Mar 07 05:18 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 02Sale1.1320,00022,50011,808,900Mar 02 05:16 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 01Sale1.13114,600130,04611,828,900Mar 02 05:16 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 28Sale1.1225,50028,59311,943,500Mar 02 05:16 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 27Sale1.13150,000168,96511,969,000Feb 27 05:42 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 24Sale1.1433,00037,50512,119,000Feb 27 05:42 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 23Sale1.16150,000174,01512,152,000Feb 27 05:42 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 22Sale1.11109,336121,58212,302,000Feb 22 04:52 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 21Sale1.1052,16457,61012,411,336Feb 22 04:52 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 17Sale1.1130033412,463,500Feb 22 04:52 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 16Sale1.10150,000165,25012,463,800Feb 16 05:35 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 15Sale1.1140,09044,50012,613,800Feb 16 05:35 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 14Sale1.10115,000126,50012,653,890Feb 16 05:35 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 13Sale1.1067,00074,02212,768,890Feb 13 05:13 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 10Sale1.1146,00850,83912,835,890Feb 13 05:13 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 09Sale1.1163,40270,42112,881,898Feb 13 05:13 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 08Sale1.06529,300561,74212,945,300Feb 08 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 07Sale1.116,2006,86113,474,600Feb 08 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 06Sale1.1028,02730,94213,480,800Feb 08 05:24 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 03Sale1.1253,43359,69013,508,827Feb 03 04:40 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 02Sale1.133,2003,61613,562,260Feb 03 04:40 PM
NORTH TIDE CAPITAL, LLC10% OwnerFeb 01Sale1.1322,00024,94113,565,460Feb 03 04:40 PM
Varghese Santosh TChief Medical OfficerJan 28Sale1.1142947674,037Jan 31 06:43 PM
Varghese Santosh TChief Medical OfficerDec 31Sale1.1213,79015,47874,466Jan 04 06:48 PM
Varghese Santosh TChief Medical OfficerOct 01Sale1.1471080988,256Oct 04 07:35 PM
Varghese Santosh TChief Medical OfficerAug 02Sale1.0712,55913,43888,966Aug 02 07:07 PM
Varghese Santosh TVP, Medical & Reg AffairsJul 01Sale1.21366443101,525Jul 06 05:12 PM